Synopsis

Source of validity: Scientific
Rating (out of 5): 5

Digitalis, derived from the foxglove plant (Digitalis purpurea), is scientifically validated for the treatment of certain heart conditions, particularly congestive heart failure and atrial fibrillation. The active compounds, known as cardiac glycosides (primarily digoxin and digitoxin), have been used in medicine since the late 18th century following the pioneering work of William Withering. These glycosides work by inhibiting the sodium-potassium ATPase pump in cardiac cells, which leads to increased intracellular calcium concentrations. This effect enhances cardiac contractility (positive inotropic effect), slows heart rate, and improves cardiac output in patients with weakened hearts or arrhythmias.

Numerous clinical studies and decades of clinical practice have established the efficacy of digitalis glycosides in improving symptoms of heart failure, although they have a narrow therapeutic window and can cause significant toxicity if not carefully dosed. The use of digitalis is now more selective due to the availability of newer heart failure treatments, but it remains an important option, particularly in patients with concomitant atrial fibrillation and heart failure. Major medical guidelines recognize digoxin (a principal digitalis glycoside) as a treatment option for specific indications in heart failure and arrhythmia management. Thus, the use of digitalis for heart "weakness" (heart failure) is grounded in robust scientific evidence.

More about Digitalis
More about Heart (weakness)

Other ingredients used for Heart (weakness)

Other health conditions supported by Digitalis

Products containing Digitalis